Report Detail
Global (United States, European Union and China) Pulmonary Hypertension Drug Market Research Report 2019-2025
- RnM3648388 |
- 06 August, 2019 |
- Global |
- 114 Pages |
- QYResearch |
- Pharma & Healthcare
Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats other life-threatening diseases such as arrhythmias, ryanoids syndrome, cephalagra, and angina.
In 2019, the market size of Pulmonary Hypertension Drug is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Pulmonary Hypertension Drug.
This report studies the global market size of Pulmonary Hypertension Drug, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Pulmonary Hypertension Drug sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
GlaxoSmithKline plc
Novartis AG
Merck & Co., Inc.
Abbott Laboratories
Boehringer Ingelheim GmbH
AstraZeneca plc
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries Ltd.
Vectura Group plc
Pfizer Inc.
Market Segment by Product Type
Prostacyclin and Prostacyclin Analogs
Endothelin Receptor Antagonists
Phosphodiesterase-5 Inhibitors
Soluble Guanylate Cyclase Stimulators
Market Segment by Application
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Pulmonary Hypertension Drug status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Pulmonary Hypertension Drug manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Pulmonary Hypertension Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Pulmonary Hypertension Drug Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Prostacyclin and Prostacyclin Analogs
- 1.3.3 Endothelin Receptor Antagonists
- 1.3.4 Phosphodiesterase-5 Inhibitors
- 1.3.5 Soluble Guanylate Cyclase Stimulators
- 1.4 Market Segment by Application
- 1.4.1 Global Pulmonary Hypertension Drug Market Share by Application (2019-2025)
- 1.4.2 Early-stage Drug Candidates (Phase I & Phase II)
- 1.4.3 Late-stage Drug Candidates (Phase III & Registration Phase)
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Pulmonary Hypertension Drug Market Size
- 2.1.1 Global Pulmonary Hypertension Drug Revenue 2014-2025
- 2.1.2 Global Pulmonary Hypertension Drug Sales 2014-2025
- 2.2 Pulmonary Hypertension Drug Growth Rate by Regions
- 2.2.1 Global Pulmonary Hypertension Drug Sales by Regions 2014-2019
- 2.2.2 Global Pulmonary Hypertension Drug Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Pulmonary Hypertension Drug Sales by Manufacturers
- 3.1.1 Pulmonary Hypertension Drug Sales by Manufacturers 2014-2019
- 3.1.2 Pulmonary Hypertension Drug Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Pulmonary Hypertension Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Pulmonary Hypertension Drug Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Pulmonary Hypertension Drug Market Concentration Ratio (CR5 and HHI)
- 3.3 Pulmonary Hypertension Drug Price by Manufacturers
- 3.4 Key Manufacturers Pulmonary Hypertension Drug Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Pulmonary Hypertension Drug Market
- 3.6 Key Manufacturers Pulmonary Hypertension Drug Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Prostacyclin and Prostacyclin Analogs Sales and Revenue (2014-2019)
- 4.1.2 Endothelin Receptor Antagonists Sales and Revenue (2014-2019)
- 4.1.3 Phosphodiesterase-5 Inhibitors Sales and Revenue (2014-2019)
- 4.1.4 Soluble Guanylate Cyclase Stimulators Sales and Revenue (2014-2019)
- 4.2 Global Pulmonary Hypertension Drug Sales Market Share by Type
- 4.3 Global Pulmonary Hypertension Drug Revenue Market Share by Type
- 4.4 Pulmonary Hypertension Drug Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Pulmonary Hypertension Drug Sales by Application
6 United States
- 6.1 United States Pulmonary Hypertension Drug Breakdown Data by Company
- 6.2 United States Pulmonary Hypertension Drug Breakdown Data by Type
- 6.3 United States Pulmonary Hypertension Drug Breakdown Data by Application
7 European Union
- 7.1 European Union Pulmonary Hypertension Drug Breakdown Data by Company
- 7.2 European Union Pulmonary Hypertension Drug Breakdown Data by Type
- 7.3 European Union Pulmonary Hypertension Drug Breakdown Data by Application
8 China
- 8.1 China Pulmonary Hypertension Drug Breakdown Data by Company
- 8.2 China Pulmonary Hypertension Drug Breakdown Data by Type
- 8.3 China Pulmonary Hypertension Drug Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Pulmonary Hypertension Drug Breakdown Data by Company
- 9.2 Rest of World Pulmonary Hypertension Drug Breakdown Data by Type
- 9.3 Rest of World Pulmonary Hypertension Drug Breakdown Data by Application
- 9.4 Rest of World Pulmonary Hypertension Drug Breakdown Data by Countries
- 9.4.1 Rest of World Pulmonary Hypertension Drug Sales by Countries
- 9.4.2 Rest of World Pulmonary Hypertension Drug Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 GlaxoSmithKline plc
- 10.1.1 GlaxoSmithKline plc Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.1.4 Pulmonary Hypertension Drug Product Introduction
- 10.1.5 GlaxoSmithKline plc Recent Development
- 10.2 Novartis AG
- 10.2.1 Novartis AG Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.2.4 Pulmonary Hypertension Drug Product Introduction
- 10.2.5 Novartis AG Recent Development
- 10.3 Merck & Co., Inc.
- 10.3.1 Merck & Co., Inc. Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.3.4 Pulmonary Hypertension Drug Product Introduction
- 10.3.5 Merck & Co., Inc. Recent Development
- 10.4 Abbott Laboratories
- 10.4.1 Abbott Laboratories Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.4.4 Pulmonary Hypertension Drug Product Introduction
- 10.4.5 Abbott Laboratories Recent Development
- 10.5 Boehringer Ingelheim GmbH
- 10.5.1 Boehringer Ingelheim GmbH Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.5.4 Pulmonary Hypertension Drug Product Introduction
- 10.5.5 Boehringer Ingelheim GmbH Recent Development
- 10.6 AstraZeneca plc
- 10.6.1 AstraZeneca plc Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.6.4 Pulmonary Hypertension Drug Product Introduction
- 10.6.5 AstraZeneca plc Recent Development
- 10.7 F. Hoffmann-La Roche AG
- 10.7.1 F. Hoffmann-La Roche AG Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.7.4 Pulmonary Hypertension Drug Product Introduction
- 10.7.5 F. Hoffmann-La Roche AG Recent Development
- 10.8 Teva Pharmaceutical Industries Ltd.
- 10.8.1 Teva Pharmaceutical Industries Ltd. Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.8.4 Pulmonary Hypertension Drug Product Introduction
- 10.8.5 Teva Pharmaceutical Industries Ltd. Recent Development
- 10.9 Vectura Group plc
- 10.9.1 Vectura Group plc Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.9.4 Pulmonary Hypertension Drug Product Introduction
- 10.9.5 Vectura Group plc Recent Development
- 10.10 Pfizer Inc.
- 10.10.1 Pfizer Inc. Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Pulmonary Hypertension Drug
- 10.10.4 Pulmonary Hypertension Drug Product Introduction
- 10.10.5 Pfizer Inc. Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Pulmonary Hypertension Drug Sales Channels
- 11.2.2 Pulmonary Hypertension Drug Distributors
- 11.3 Pulmonary Hypertension Drug Customers
12 Market Forecast
- 12.1 Global Pulmonary Hypertension Drug Sales and Revenue Forecast 2019-2025
- 12.2 Global Pulmonary Hypertension Drug Sales Forecast by Type
- 12.3 Global Pulmonary Hypertension Drug Sales Forecast by Application
- 12.4 Pulmonary Hypertension Drug Forecast by Regions
- 12.4.1 Global Pulmonary Hypertension Drug Sales Forecast by Regions 2019-2025
- 12.4.2 Global Pulmonary Hypertension Drug Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Pulmonary Hypertension Drug. Industry analysis & Market Report on Pulmonary Hypertension Drug is a syndicated market report, published as Global (United States, European Union and China) Pulmonary Hypertension Drug Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Pulmonary Hypertension Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
